Mitsubishi UFJ Trust & Banking Corp Has $16.07 Million Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

Mitsubishi UFJ Trust & Banking Corp lowered its holdings in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 4.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 81,783 shares of the medical research company's stock after selling 3,826 shares during the period. Mitsubishi UFJ Trust & Banking Corp's holdings in IQVIA were worth $16,071,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of the stock. Raymond James Financial Inc. bought a new stake in shares of IQVIA in the 4th quarter worth approximately $236,120,000. American Century Companies Inc. lifted its stake in IQVIA by 396.0% in the fourth quarter. American Century Companies Inc. now owns 1,134,737 shares of the medical research company's stock valued at $222,987,000 after buying an additional 905,960 shares during the last quarter. FMR LLC grew its position in shares of IQVIA by 38.7% during the third quarter. FMR LLC now owns 2,887,342 shares of the medical research company's stock worth $684,213,000 after acquiring an additional 804,963 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in shares of IQVIA by 46.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company's stock worth $437,378,000 after acquiring an additional 583,396 shares during the period. Finally, Nordea Investment Management AB lifted its position in IQVIA by 47.4% in the 4th quarter. Nordea Investment Management AB now owns 1,405,281 shares of the medical research company's stock valued at $277,908,000 after purchasing an additional 452,029 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

IQVIA Trading Up 0.3 %

IQVIA stock traded up $0.59 during midday trading on Wednesday, reaching $171.83. The stock had a trading volume of 369,690 shares, compared to its average volume of 1,301,857. IQVIA Holdings Inc. has a twelve month low of $169.37 and a twelve month high of $252.88. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. The firm has a market cap of $30.30 billion, a price-to-earnings ratio of 22.91, a PEG ratio of 1.99 and a beta of 1.50. The firm's fifty day simple moving average is $192.05 and its two-hundred day simple moving average is $205.13.

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Equities analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on IQV shares. Truist Financial restated a "buy" rating and issued a $263.00 price target (up previously from $261.00) on shares of IQVIA in a research note on Monday, February 10th. Barclays cut their target price on IQVIA from $255.00 to $235.00 and set an "overweight" rating on the stock in a research note on Monday, February 3rd. Royal Bank of Canada reissued an "outperform" rating and set a $270.00 price target on shares of IQVIA in a report on Monday, February 10th. Bank of America reduced their price objective on shares of IQVIA from $255.00 to $235.00 and set a "buy" rating for the company in a report on Friday, December 13th. Finally, Citigroup lowered their target price on shares of IQVIA from $225.00 to $210.00 and set a "neutral" rating on the stock in a research note on Tuesday, March 4th. Five equities research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $249.05.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.